Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3215 | RAPID-3 Wiki | 1.00 |
| drug2920 | Placebo (PB0) Wiki | 1.00 |
| drug1849 | IER-R (posttraumatic stress) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003095 | Collagen Diseases NIH | 0.35 |
| D012216 | Rheumatic Diseases NIH | 0.32 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The National Institute of Medical Sciences and Nutrition is a national reference center for rheumatic diseases that belongs to The National Institutes of Health, and has Federal founding. More than 8,000 patients with a wide variety of rheumatologic diagnosis receive medical care. On March 2020, the WHO announced COVID-19 outbreak a pandemic. The first case was registered in Mexico on February 2020. In March 2020, the Mexican Government requested that our Institution should restrict health care to exclusively COVID-19 patients; accordingly, outpatient consultations were, and up to August 2020 still, hold on. Meanwhile, when possible, the Department of Immunology and Rheumatology has implemented an "on-demand", non-organized patient´s health care, through email and phone contact; nonetheless, and due to the middle-low socioeconomic status of most of our patients and limited technical resources available at our Institution, the attempt has been challenging.
Description: To determinate the proportion of the rheumatic disease patients affected in their usual medical care during the COVID-19 pandemic in our Institution with the COVID-19 survey (locally development)
Measure: Change in the pattern of the usual medical care among the rheumatic disease patients Time: At study inclusion (The first medical consultation posterior to open the external outpatient's service, post COVID-19 pandemic)Description: Change in the activity disease measured as RAPID-3 of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 30 a > number > disease activity
Measure: Change in the patient's activity disease Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-upDescription: Change in the activity disease measured by their rheumatologist (4 questions) of the rheumatic disease patients in a 6 months follow-up. The results will express with 3 categories (without activity, low activity, moderate activity, high activity)
Measure: Change in the patient's activity disease measures by their rheumatologist Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-upDescription: Change in the quality of life measured as WHOQOL-BREF of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 100 a > number > quality of life
Measure: Change in patient´s quality of life Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-upDescription: Change in the psychopathology measured as DASS-21 instrument (depression and anxiety) of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 8 a cut of point > 8 suggests depression and stress presence, and > 5 suggests anxiety presence
Measure: Change in patient´s depression and anxiety Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-upDescription: Change in the psychopathology measured as IER-R (posttraumatic stress) of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 88 a cut of point > 24 would be significant
Measure: Change in patient´s posttraumatic stress Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports